WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 202320

CAS#: 943319-70-8 (free base)

Description: Ponatinib is an orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Multitargeted tyrosine kinase inhibitor AP24534 inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3).

Chemical Structure

CAS# 943319-70-8 (free base)

Theoretical Analysis

MedKoo Cat#: 202320
Name: Ponatinib
CAS#: 943319-70-8 (free base)
Chemical Formula: C29H27F3N6O
Exact Mass: 532.21984
Molecular Weight: 532.56
Elemental Analysis: C, 65.40; H, 5.11; F, 10.70; N, 15.78; O, 3.00

Size Price Shipping out time Quantity
100mg USD 90 Same day
200mg USD 150 Same day
500mg USD 350 Same day
1g USD 550 Same day
2g USD 950 Same day
5g USD 1750 2 Weeks
10g USD 2750 2 Weeks
20g USD 4650 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-02-27. Prices are subject to change without notice.

Ponatinib free base, purity > 98%, is in stock. The same day shipping out after order is received.

Related CAS #: 943319-70-8 (free base)   1114544-31-8 (HCl)   1232836-25-7 (tris-hydrochloride)    

Synonym: AP24534; AP-24534; AP 24534; Ponatinib. Brand name: Iclusig.

IUPAC/Chemical Name: 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide.


InChi Code: InChI=1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39)


white solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Ponatinib free base is soluble in DMSO at 50 mg/mL; soluble in ethanol at 25 mg/mL with warming; very poorly soluble in water. The solubility of ponatinib in pH 1.7, 2.7, and 7.5 buffers is 7790 mcg/ml, 3.44 mcg/ml, and 0.16 mcg/ml, respectively, indicating a decrease in solubility with increasing pH.

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:

Preparing Stock Solutions

The following data is based on the product molecular weight 532.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Oaxaca DM, Yang-Reid SA, Ross JA, Rodriguez G, Staniswalis JG, Kirken RA. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment. Tumour Biol. 2016 Jul 21. [Epub ahead of print] PubMed PMID: 27444277.

2: Dessilly G, Panin N, Elens L, Haufroid V, Demoulin JB. Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib. Sci Rep. 2016 Jul 12;6:29559. doi: 10.1038/srep29559. PubMed PMID: 27405085; PubMed Central PMCID: PMC4941718.

3: Abid MB, De Mel S. Does ponatinib cross the blood-brain barrier? Br J Haematol. 2016 Jun 28. doi: 10.1111/bjh.14222. [Epub ahead of print] PubMed PMID: 27352067.

4: Breccia M, Abruzzese E, Iurlo A, Gozzini A, Isidori A, Gangemi D, Pregno P, Alimena G. Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase. Haematologica. 2016 Jun;101(6):e267-8. doi: 10.3324/haematol.2016.145623. Epub 2016 May 31. PubMed PMID: 27252515.

5: Engel NW, Constantin A, Fowlkes S, Assouline S. Unexpected Success of Watch and Wait Strategy in a Ponatinib-Intolerant Patient With Chronic Myeloid Leukemia. J Oncol Pract. 2016 Jun;12(6):592-4. doi: 10.1200/JOP.2016.012054. Epub 2016 May 31. PubMed PMID: 27246687.

6: Sparidans RW, Kort A, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for ponatinib and N-desmethyl ponatinib in mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Jun 15;1023-1024:24-9. doi: 10.1016/j.jchromb.2016.04.049. Epub 2016 May 2. PubMed PMID: 27179188.

7: Matsuda Y, Yamauchi T, Hosono N, Uzui K, Negoro E, Morinaga K, Nishi R, Yoshida A, Kimura S, Maekawa T, Ueda T. Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells. Cancer Sci. 2016 Jul;107(7):1029-38. doi: 10.1111/cas.12965. Epub 2016 Jun 21. PubMed PMID: 27166836; PubMed Central PMCID: PMC4946706.

8: Narasimhan NI, Dorer DJ, Davis J, Turner CD, Sonnichsen D. Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects. Clin Pharmacol Drug Dev. 2015 Sep;4(5):354-60. doi: 10.1002/cpdd.182. Epub 2015 May 1. PubMed PMID: 27137144.

9: Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, Etienne G, Nicolini FE, le Coutre P, Clark RE, Stenke L, Andorsky D, Oehler V, Lustgarten S, Rivera VM, Clackson T, Haluska FG, Baccarani M, Cortes JE, Guilhot F, Hochhaus A, Hughes T, Kantarjian HM, Shah NP, Talpaz M, Deininger MW; EPIC investigators. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016 May;17(5):612-21. doi: 10.1016/S1470-2045(16)00080-2. Epub 2016 Apr 12. PubMed PMID: 27083332.

10: Fava C, Saglio G. Ponatinib for chronic myeloid leukaemia: future perspectives. Lancet Oncol. 2016 May;17(5):546-7. doi: 10.1016/S1470-2045(16)30064-X. Epub 2016 Apr 12. PubMed PMID: 27083331.

11: Tournaire G, Despas F, Huguet F, Montastruc JL, Bondon-Guitton E. Peripheral arterial occlusive disease during ponatinib therapy after failure of imatinib: a case report. J Clin Pharm Ther. 2016 Jun;41(3):360-361. doi: 10.1111/jcpt.12383. Epub 2016 Mar 23. PubMed PMID: 27009771.

12: Breccia M, Colafigli G, Quattrocchi L, Abruzzese E, Alimena G. Cutaneous Lesions Anticipating Accelerated Phase of Multidrug Resistant Chronic Myeloid Leukemia Responsive to Ponatinib. Mediterr J Hematol Infect Dis. 2016 Feb 20;8(1):e2016016. doi: 10.4084/MJHID.2016.016. eCollection 2016. PubMed PMID: 26977275; PubMed Central PMCID: PMC4771144.

13: Darwish HW, Bakheit AH, Abdelhameed AS, AlKhairallah AS. Micellar Enhanced Spectrofluorimetric Method for the Determination of Ponatinib in Human Plasma and Urine via Cremophor RH 40 as Sensing Agent. Int J Anal Chem. 2015;2015:210503. doi: 10.1155/2015/210503. Epub 2015 Dec 31. PubMed PMID: 26880920; PubMed Central PMCID: PMC4736017.

14: Saglio G, Fava C. BCR-ABL1 mutation ≠ ponatinib resistance. Blood. 2016 Feb 11;127(6):666-7. doi: 10.1182/blood-2015-12-685149. PubMed PMID: 26869304.

15: Kang Z, Ji Y, Zhang G, Qu Y, Zhang L, Jiang W. Ponatinib attenuates experimental pulmonary arterial hypertension by modulating Wnt signaling and vasohibin-2/vasohibin-1. Life Sci. 2016 Mar 1;148:1-8. doi: 10.1016/j.lfs.2016.02.017. Epub 2016 Feb 6. PubMed PMID: 26860892.

16: Ponatinib. Aust Prescr. 2015 Dec;38(6):221-2. Epub 2015 Sep 18. Review. PubMed PMID: 26843719; PubMed Central PMCID: PMC4674036.

17: Sidaway P. Haematological cancer: Ponatinib in CML - keeping PACE with multiple mutations. Nat Rev Clin Oncol. 2016 Mar;13(3):135. doi: 10.1038/nrclinonc.2016.13. Epub 2016 Feb 2. PubMed PMID: 26831184.

18: Parker WT, Yeung DT, Yeoman AL, Altamura HK, Jamison BA, Field CR, Hodgson JG, Lustgarten S, Rivera VM, Hughes TP, Branford S. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib. Blood. 2016 Apr 14;127(15):1870-80. doi: 10.1182/blood-2015-09-666214. Epub 2016 Jan 14. PubMed PMID: 26773037; PubMed Central PMCID: PMC4832506.

19: Quilot FM, Georges M, Favrolt N, Beltramo G, Foignot C, Grandvuillemin A, Montani D, Bonniaud P, Camus P. Pulmonary hypertension associated with ponatinib therapy. Eur Respir J. 2016 Feb;47(2):676-9. doi: 10.1183/13993003.01110-2015. Epub 2016 Jan 7. PubMed PMID: 26743481.

20: Breccia M, Alimena G. Ponatinib in chronic myeloid leukaemia: ready for first-line? Lancet Haematol. 2015 Sep;2(9):e352-3. doi: 10.1016/S2352-3026(15)00130-1. Epub 2015 Jul 30. PubMed PMID: 26685767.

Additional Information

Ponatinib was approved ion 2012, but temporarily suspended sales on 31 October 2013 because of "the risk of life-threatening blood clots and severe narrowing of blood vessels". This suspension was partially lifted